Please select the option that best describes you:
Topics:
Endocrinology • Lipid Disorders
What are some of the benefits of the newly approved Lerochol drug over traditional PCSK9 inhibitors for the treatment of familial hyperlipidemia?
Answer from: at Academic Institution
Lerodalcibep was approved this past December and uses a different mechanism to inhibit PCSK9. Its potential advantages include once monthly dosing and stability at room temperature for 3 months. It appears to have similar efficacy to the PCSK9 monoclonal antibody therapies lowering LDL 55-60%. Disad...
Sign In or Register to read more
Answer from: at Academic Institution
While there are no CV outcome studies yet with lerodalcibep, a 3rd generation PCSK9 inhibitor, the clinical data shows impressive LDL-reducing efficacy.
The advantages are practical ones:
monthly injection
stability at room temperature
smaller volume of injection.
Based on the beneficial CV...
Answer from: at Academic Institution
Lerochol is a small molecule/fusion protein designed to inhibit PCSK9 called lerodalcibep-liga. It will become available in spring/summer 2026. It results in LDL-C reduction of 50-60% so similar efficacy to the monoclonal antibodies. It has been studied in heterozygous familial hypercholesterolemia ...